The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Philip M. P. Poortmans

Department of Radiation Oncology

Dr. Bernard Verbeeten Instituut

Tilburg

Netherlands

[email]@bvi.nl

Name/email consistency: high

 
 
 
 
 
 
 

Affiliation

  • Department of Radiation Oncology, Dr. Bernard Verbeeten Instituut, Tilburg, Netherlands. 2001 - 2009

References

  1. Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial. Poortmans, P.M., Collette, L., Horiot, J.C., Van den Bogaert, W.F., Fourquet, A., Kuten, A., Noordijk, E.M., Hoogenraad, W., Mirimanoff, R.O., Pierart, M., Van Limbergen, E., Bartelink, H. Radiother. Oncol (2009) [Pubmed]
  2. The addition of a boost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer. A summary of the results of EORTC 22881-10882 "boost versus no boost" trial. Poortmans, P.M., Collette, L., Bartelink, H., Struikmans, H., Van den Bogaert, W.F., Fourquet, A., Jager, J.J., Hoogenraad, W., Müller, R.P., Dubois, J.B., Bolla, M., Van Der Hulst, M., Wárlám-Rodenhuis, C.C., Pierart, M., Horiot, J.C. Cancer. Radiother (2008) [Pubmed]
  3. Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder. Poortmans, P.M., Richaud, P., Collette, L., Ho Goey, S., Pierart, M., Van Der Hulst, M., Bolla, M. Acta. Oncol (2008) [Pubmed]
  4. Evidence based radiation oncology: breast cancer. Poortmans, P. Radiother. Oncol (2007) [Pubmed]
  5. Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Poortmans, P., Bossi, A., Vandeputte, K., Bosset, M., Miralbell, R., Maingon, P., Boehmer, D., Budiharto, T., Symon, Z., van den Bergh, A.C., Scrase, C., Van Poppel, H., Bolla, M. Radiother. Oncol (2007) [Pubmed]
  6. Quality assurance in the EORTC randomized trial 22922/10925 investigating the role of irradiation of the internal mammary and medial supraclavicular lymph node chain works. Poortmans, P., Kouloulias, V., van Tienhoven, G., Collette, L., Struikmans, H., Venselaar, J.L., Van den Bogaert, W., Davis, J.B., Lambin, P. Strahlenther. Onkol (2006) [Pubmed]
  7. Quality assurance in the EORTC phase III randomised 'boost vs. no boost' trial for breast conserving therapy: comparison of the results of two individual case reviews performed early and late during the accrual period. Poortmans, P.M., Ataman, F., Davis, J.B., Bartelink, H., Horiot, J.C., Pierart, M., Collette, L., Van Tienhoven, G. Radiother. Oncol (2005) [Pubmed]
  8. The quality assurance programme of the Radiotherapy Group of the European Organisation for Research and Treatment of Cancer: past, present and future. Poortmans, P.M., Davis, J.B., Ataman, F., Bernier, J., Horiot, J.C. Eur. J. Surg. Oncol (2005) [Pubmed]
  9. Quality assurance of EORTC trial 22922/10925 investigating the role of internal mammary--medial supraclavicular irradiation in stage I-III breast cancer: the individual case review. Poortmans, P., Kouloulias, V.E., Venselaar, J.L., Struikmans, H., Davis, J.B., Huyskens, D., van Tienhoven, G., Hurkmans, C., Mijnheer, B., Van den Bogaert, W. Eur. J. Cancer (2003) [Pubmed]
  10. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. Poortmans, P.M., Kluin-Nelemans, H.C., Haaxma-Reiche, H., Van't Veer, M., Hansen, M., Soubeyran, P., Taphoorn, M., Thomas, J., Van den Bent, M., Fickers, M., Van Imhoff, G., Rozewicz, C., Teodorovic, I., van Glabbeke, M. J. Clin. Oncol. (2003) [Pubmed]
  11. The potential impact of treatment variations on the results of radiotherapy of the internal mammary lymph node chain: a quality-assurance report on the dummy run of EORTC Phase III randomized trial 22922/10925 in Stage I--III breast cancer(1). Poortmans, P.M., Venselaar, J.L., Struikmans, H., Hurkmans, C.W., Davis, J.B., Huyskens, D., van Tienhoven, G., Vlaun, V., Lagendijk, J.J., Mijnheer, B.J., De Winter, K.A., Van der Hulst, M.H., Van den Bogaert, W.F. Int. J. Radiat. Oncol. Biol. Phys. (2001) [Pubmed]
  12. Always on a Friday? Time pattern of referral for spinal cord compression. Poortmans, P., Vulto, A., Raaijmakers, E. Acta. Oncol (2001) [Pubmed]
 
WikiGenes - Universities